BCAT-IN-4 Secrets
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, although